


Interview with Dr. Suresh Ramalingam,
Director, Lung Cancer Program,
Winship Cancer Institute at Emory University:
Managing Locally Advanced (Stage III) NSCLC



By
Howard (Jack) West, MD
Medical Oncologist
President & CEO
GRACE

April, 2009

Stage III/Locally Advanced NSCLC



- Approximately 40-45% of new presentations of NSCLC



Typical Approaches to Definitive Chemo/Radiation for Locally Advanced NSCLC

Option 1

Radiation daily Mon –Fri over ~7 weeks

Cisplatin/Etoposide
Full Dose Chemotherapy

Cisplatin/Etoposide
Full Dose Chemotherapy

Option 2

Radiation daily Mon –Fri over ~7 weeks

Carbo/
Taxol
weekly

Carbo/
Taxol
weekly

Carbo/
Taxol
weekly

Carbo/
Taxol
weekly

Carbo/
Taxol
weekly

Carbo/
Taxol
weekly

Carbo/
Taxol
weekly



Hoosier Oncology Group (HOG) Trial: Direct Test of Consolidation Taxotere (Docetaxel)

Unresectable
Stage III NSCLC
Cisplatin/etoposide x2
w/concurrent XRT
to 61 Gy

→
No PD
PS 0-2

R
A
N
D

→
Consolidation
Taxotere every 3 weeks
x 3 cycles

→
Observation

Accrued: 203 pts


→

147 pts (68%)

Hanna, J Clin Oncol 2008




HOG Trial: Overall Survival



Hanna, J Clin Oncol 2008



Locally Advanced Multimodality Protocol (LAMP) (ACR 427): Trial Design



Belani, J Clin Oncol, 2005

